bluebird bio公司动态 - bluebird bio计划进行了1.50美元每股的15亿美元普通股二次发行，拥有三种经FDA批准的基因疗法治疗，并计划进行商业化[1] - bluebird bio最新获得FDA批准的LYFGENIA是一种针对镰状细胞病的一次性治疗方案，每位患者的价格约为310万美元，比Vertex Pharmaceutical的Casgevy高出40%[1] - bluebird bio专注于为严重遗传病和罕见病开发基因疗法，特别是镰状细胞病（SCD）和β-地中海贫血（BT）[4] - bluebird bio拥有三种经FDA批准的基因疗法：ZYNTEGLO、SKYSONA和LYFGENIA，分别用于治疗β-地中海贫血、早期活动性脑白质脑白质白质脑白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质白质